Rare disease biopharma companies weigh in on FDA's new innovation hub

AstraZeneca's Alexion, BridgeBio, BioMarin, Ultragenyx and others, including Sen. Bob Casey (D-PA), recently weighed in on the details of a new cross-cutting FDA collaboration hub focused on rare disease treatments. The companies raised questions over ...